Geneva, Switzerland, April 30, 2026-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...
Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique ...
Geneva, Switzerland, January 8, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...
Earnings call Addex Therapeutics reported a decrease in income to CHF 0.2 million for 2025 (vs CHF 0.4 million in 2024) due to the completion of the Indivior research phase, with R&D expenses down to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results